TargetMol

BMS-193884

Product Code:
 
TAR-T30501
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30501-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30501-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30501-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BMS-193884 is an oral endothelin antagonist for the treatment of congestive heart failure (CHF) and pulmonary arterial hypertension.
CAS:
176960-47-7
Formula:
C20H17N3O4S
Molecular Weight:
395.43
Purity:
0.98
SMILES:
Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(cc2)-c2ncco2)c1C

References

1. Dhaun N, Strachan FE, Newby DE, Johnston NR, Ford NF, Hammett JL, Palmisano M, Webb DJ. Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men. Br J Clin Pharmacol. 2005 Dec;60(6):611-22. PubMed PMID: 16305585; PubMed Central PMCID: PMC1884878. 2. Humphreys WG, Obermeier MT, Barrish JC, Chong S, Marino AM, Murugesan N, Wang-Iverson D, Morrison RA. Application of structure-metabolism relationships in the identification of a selective endothelin A antagonist, BMS-193884, with favourable pharmacokinetic properties. Xenobiotica. 2003 Nov;33(11):1109-23. PubMed PMID: 14660175. 3. De Smet HR, Menadue MF, Oliver JR, Phillips PA. Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats. Clin Exp Pharmacol Physiol. 2003 Apr;30(4):278-83. PubMed PMID: 12680847. 4. Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl] - 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem. 2003 Jan 2;46(1):125-37. PubMed PMID: 12502366.